Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab vs Ustekinumab for Fibrostenotic Crohn's Disease
NCT07177118Phase 3Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Oct 2025
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, open-label trial of risankizumab in Crohn's disease (2 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Clinical-Radiological Composite Endpoint at 24 weeks. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07177118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07177118.